🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — August 26, 2026

The sole filing in today's IPO Pipeline stream is Daré Bioscience's S-1 registration for a proposed public offering, marking a critical juncture for the company as it transitions to a dual-path business model (503B compounded products and consumer health). The filing follows a private placement and registered direct offering that closed on August 17, 2026, at $1.37 per share, indicating strong capital-raising momentum. However, the company faces existential risks: a Nasdaq delisting hearing was held on August 25, 2026, and it has negative stockholders' equity with no material revenue expected from product sales in 2026. The sentiment is mixed, reflecting the high-risk/high-reward nature of the offering. The S-1 provides a detailed look at the company's operational pivot, with its first 503B product (DARE to PLAY Sildenafil Cream) available for pre-order since December 2025 and its first consumer health product (Flora Sync LF5) launched in June 2026. Investors should weigh the potential upside of the new product lines against the immediate need for additional capital and the overhang of the Nasdaq compliance issue.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — August 26, 2026

The August 26, 2026 trading suspension and delisting landscape is dominated by a cluster of Nasdaq compliance failures, with three micro-cap companies (American Resources Corp, Atlantic American Corp, and CaliberCos Inc.) receiving deficiency or delisting notices within a single week. This pattern suggests a potential tightening of Nasdaq's enforcement or a broader financial reporting strain among smaller issuers. In contrast, Avalanche Treasury Corp successfully resolved its deficiency, providing a positive data point. The voluntary delisting of Kraft Heinz Co from Nasdaq to transfer to the NYSE is a non-event from a regulatory risk perspective but highlights a strategic listing choice. Period-over-period data from the filings is sparse, but the aggregate trend shows a 60% failure rate (3 out of 5) for companies facing compliance issues, with two of those failures stemming from chronic late filings, indicating deeper operational and financial control problems. The most critical development is the high materiality (8-9/10) of the three negative delisting notices, which carry immediate downside risk for equity holders. No insider trading activity or forward-looking guidance was reported in any of the filings, limiting the depth of sentiment analysis but also signaling a lack of management-led confidence signals during these critical periods.

5 high priority 5 total filings
· daily

US Executive Officer Management Changes SEC — August 26, 2026

This digest of 20 regulatory filings reveals a period of significant leadership transition across the US equity markets, with a notable concentration of CEO and C-suite changes in the industrial and technology sectors. The most material development is the planned retirement of Waste Management's CEO Jim Fish after a decade, a well-flagged succession that signals stability. In contrast, the CFO departures at Duos Technologies and SS Innovations, while amicable, create near-term uncertainty. A clear theme of strategic realignment is evident, with Micron Technology promoting internally to align with its AI-driven growth strategy and Gevo expanding executive roles to support commercial execution. The data also highlights a strong focus on long-term incentive alignment, with Key Tronic and Novelis implementing performance-based compensation tied to EBITDA and project milestones. While most filings are routine, the combination of a major CEO transition, multiple CFO changes, and strategic promotions creates a landscape of both risk and opportunity for investors monitoring management quality and strategic direction.

20 high priority 20 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 26, 2026

The August 26, 2026, digest reveals a period of significant executive and board-level transitions across the US market, with a clear emphasis on succession planning and strategic realignment. The most critical development is the CEO transition at Waste Management (WM), a Dow Jones component, signaling a major leadership change for a market leader. The filings also show a strong trend of companies appointing new CFOs (CuriosityStream, Duos Technologies, CPI Card Group) and promoting internal talent to key operational roles (Micron, Gevo, McEwen), suggesting a focus on execution and growth. While most changes are routine, the shareholder dissent at Helen of Troy's AGM (14.1% against for one director) and the departure of a director to join Reddit (Rumble) provide nuanced insights into governance and talent dynamics. Overall, the period is characterized by proactive board and management refreshment, with a positive tilt in sentiment, particularly for companies with clear growth strategies like Micron and Gevo. The data reveals no significant insider selling or negative period-over-period trends, but rather a focus on positioning for future performance, with several companies reaffirming or raising guidance (Gevo, CuriosityStream).

20 high priority 20 total filings
· daily

USA Insider Trading Pulse — August 26, 2026

The August 26, 2026 insider trading pulse reveals a pronounced divergence between executive selling and strategic buying. A dominant theme is the heavy, pre-planned selling by C-suite executives at high-growth tech companies like DoorDash, Intapp, and Dell Technologies, where CEO Tony Xu alone monetized $6.8M in stock. Conversely, a clear contrarian buying signal emerges from beaten-down sectors, with the CEO of Jushi Holdings making a $184K open-market purchase and the CEO of Eos Energy receiving substantial equity awards, signaling long-term conviction. A significant institutional capital rotation is underway within the Calamos fund complex, where MetLife Investment Management is executing a multi-million dollar arbitrage, selling preferred shares in one fund to buy in another. The data also shows a cluster of director-level stock awards at Aqua Metals, suggesting a board-level refresh or incentive program. Overall, the pulse points to a market where insiders are taking profits in overvalued growth names while deploying capital into distressed value and special situations.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 26, 2026

This USA M&A & Takeover Activity digest covers 13 pre-analyzed SEC filings, dominated by SPAC-related amendments, extensions, and business combination approvals alongside two completed M&A transactions of significant scale. The most critical development is the execution of two major acquisitions: Somnigroup's $2.3 billion all-stock acquisition of Leggett & Platt, which is expected to generate $75 million in run-rate synergies but also faces $60 million in annualized non-cash charges, and Vireo Growth's acquisition of C21 Investments, expanding its Nevada footprint to 14 dispensaries and 159,000 sq. ft. of cultivation capacity. On the SPAC front, Bleichroeder Acquisition Corp. II secured shareholder approval for its combination with Pasqal but faced a high 26 million share redemption rate, signaling mixed investor sentiment. The period-over-period enriched data reveals an active market for deSPAC processes, with several SPACs extending their deadlines (Inflection Point, Cayson, Black Hawk via a convertible note), indicating persistent challenges in finalizing deals. Insider activity is limited, but capital allocation data shows a strategic shift towards vertical integration and synergy realization, as seen in the Somnigroup and Vireo transactions. A notable portfolio-level pattern is the heightened level of gating events (shareholder meetings, redemption decisions) over the coming weeks, presenting clear catalysts for volatility in the target equities.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 26, 2026

Overnight filings from August 25-26, 2026, reveal a market bifurcated between defense/space SPACs and industrial/energy companies facing cyclical headwinds. The most significant development is the Bleichroeder Acquisition Corp. III / Ursa Major de-SPAC, a $2.3B post-money valuation deal with a $350M PIPE, signaling strong institutional appetite for defense tech. Conversely, TORM plc's 25% YoY net profit decline and Donaldson's mixed results (record sales but Industrial Filtration down 2%) highlight margin pressure in cyclical sectors. Insider activity is a key theme: significant sells by CORPAY ($1.59M) and Allison Transmission ($2.94M) contrast with a massive insider purchase of Expion360 convertible debentures ($20.3B notional), suggesting a high-conviction bet on a turnaround. The Equinox Gold 13G filing from Fairfax indicates a passive, value-oriented stake in gold. Cybersecurity risk is elevated with Boston Scientific's operational disruption, while the Charter/Cox Communications deal closes, creating a cable giant. The period-over-period data shows a clear divergence: growth in defense/space (Ursa Major revenue +143% YoY) vs. contraction in shipping (TORM revenue -11.8%) and select industrials.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 25, 2026

The five filings from the S&P 500 Technology sector reveal a concentrated pattern of insider selling, with four companies reporting significant transactions by top executives and directors, all executed under Rule 10b5-1 plans. This broad-based selling, particularly the $5.08M sale by Micron Technology's CEO and the $913K sale by CrowdStrike's CEO, suggests a cautious or profit-taking stance among management, despite the lack of negative guidance changes. Intuit's filing stands out as the only one with a positive capital allocation signal, announcing a $1.38 per share dividend, though it lacks specific period-over-period financial performance data. The absence of revenue or earnings figures in Intuit's 8-K and the lack of any forward-looking guidance changes across the filings limit the ability to identify sector-wide growth or margin trends. Overall, the dominant theme is a high level of insider monetization, which warrants close monitoring for potential sector headwinds or valuation concerns, while Intuit's dividend increase provides a contrasting signal of shareholder return commitment.

4 high priority 1 medium 5 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — August 25, 2026

This digest of 42 filings reveals a landscape dominated by significant activist and institutional activity, with a clear focus on corporate governance and value realization. The most critical development is the transformative $9.5B+ transaction between **Cox Enterprises and Charter Communications**, which reshapes the telecom landscape and creates a powerful new shareholder with board control. Activist campaigns are intensifying, with **Goldenwise Capital** nominating a director at **Phunware** and **Fund 1 Investments** taking a 9.9% activist stake in **Xponential Fitness**, signaling a push for operational improvements. A notable pattern of insider selling is emerging, with **Diana Shipping** reducing its stake in **Genco Shipping** by 1.2M shares and **Engine Capital** exiting its position in **Civeo Corp** below the 5% threshold, suggesting sector-specific concerns in shipping and energy services. Conversely, **Paine Schwartz** is aggressively accumulating shares of **Suja Life**, increasing its majority stake to 65.5% through five consecutive days of purchases at rising prices, a strong vote of confidence. The data also highlights significant dilution risk at **Edesa Biotech**, where a group's potential ownership could reach 27.8% if ownership limitations are removed. Overall, the period shows a market where large blockholders are actively deploying capital to influence strategy, while others are taking profits or reducing exposure, creating a dynamic environment for event-driven investors.

22 high priority 20 medium 42 total filings
· daily

S&P 500 Financials Sector SEC Filings — August 25, 2026

The August 25, 2026 filing batch for the S&P 500 Financials stream is dominated by insider selling activity and low-materiality administrative changes. Six of the seven filings are newly published, centered on a routine but broad board-level resignation across three Morgan Stanley crypto trust entities (Bitcoin, Solana, Ethereum), which carries negligible financial impact. The remaining three filings are Form 4 insider sales totaling approximately $3.9 million, executed by senior executives, directors, and a major 10% owner at Northern Trust, Chubb, and AFLAC. Notably, all three insider sellers are reducing positions, with two transactions executed under pre-arranged 10b5-1 plans, signaling potential portfolio rebalancing or tax planning rather than operational distress. The data reveals no period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A activity, limiting the breadth of signals but highlighting a uniform negative sentiment bias from insider transactions. The key takeaway is a cautionary signal from top-tier insiders at blue-chip financials, particularly Chubb's director selling nearly 30% of his disclosed position, which warrants monitoring for broader sector confidence. The seven filings provide actionable intelligence primarily in the insider activity and event-driven risk categories, with no immediate growth or guidance catalysts.

7 high priority 7 total filings
· daily

S&P 500 Energy Sector SEC Filings — August 25, 2026

The four filings from the S&P 500 Energy sector reveal a mixed picture of insider sentiment and corporate stability. The most significant development is the $5.47M stock sale by EOG Resources' Chairman & CEO, Ezra Yacob, which is a substantial insider divestiture that warrants close attention, especially given the stock's price level. Targa Resources is undergoing a leadership transition with a new CFO and a logistics president, which is neutral but introduces execution risk. Insider selling by a Targa director adds to the cautious tone. In contrast, a token purchase by a 10% owner of Texas Pacific Land Corp is negligible. The period-over-period data from the enriched filings was not available for trend analysis, limiting the ability to identify portfolio-level revenue or margin trends. The key takeaway is a divergence in insider behavior: significant selling at EOG and Targa versus a symbolic buy at Texas Pacific Land, suggesting a bearish lean among top executives in the mid-to-large cap E&P space.

4 high priority 4 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — August 25, 2026

The four filings from S&P 500 Consumer Staples companies reveal a mixed insider activity picture, with two significant sell-to-cover transactions by top executives at Estée Lauder and Church & Dwight, suggesting potential caution or liquidity needs, while two insider acquisitions at McCormick & Co. indicate management confidence. No period-over-period financial comparisons, forward-looking guidance, or capital allocation changes were reported in these filings, limiting trend analysis. The most critical development is the $1.57M sale by Church & Dwight's EVP of Tech & Global New Products, which, combined with Estée Lauder's $554K sale by its General Counsel, raises a moderate bearish signal for the sector. However, the McCormick insider purchases (CEO and CHRO) provide a counterbalancing bullish signal, suggesting selective confidence within the sector. The overall portfolio-level pattern is one of divergence, with no clear sector-wide theme emerging from these specific filings.

4 high priority 4 total filings
· daily

S&P 500 Industrials Sector SEC Filings — August 25, 2026

Today's insider trading filings across three S&P 500 Industrials constituents reveal a cautious tone within the sector's leadership, particularly in heavy machinery and power systems. The most significant event is the massive $7.51M stock sale by Deere & Co.'s President of Worldwide Construction & Forestry and Power Systems, Ryan Campbell, executed under a Rule 10b5-1 plan. While the use of a pre-arranged plan mitigates some direct concern, the sheer size of the sale (over $7.5 million) warrants attention, especially when paired with a $399K sale by Cummins' VP & CIO. In contrast, Otis Worldwide's filing is a routine tax-withholding transaction from an option exercise, carrying neutral sentiment. Across the three filings, no bullish insider buying was recorded, creating a negative bias. The key takeaway is a convergence of insider selling at the executive level within the agricultural and industrial machinery subsector, suggesting management may view current valuations as full or see near-term headwinds in end-markets. Investors should scrutinize upcoming earnings calls for commentary on dealer inventories and order backlogs.

3 high priority 3 total filings
· daily

US Material Events SEC 8-K Filings — August 25, 2026

The August 25, 2026 filings reveal a market actively reallocating capital toward defense, AI infrastructure, and critical minerals, evidenced by major SPAC deals and strategic acquisitions in hypersonics (Ursa Major), AI power management (Navitas/Claros), and rare earths (Rare Earths Americas). Concurrently, significant debt refinancing activity across financial and industrial names (Credit Acceptance, TPG Twin Brook, Tractor Supply) indicates a focus on optimizing balance sheets amid a rising rate environment. Governance and leadership transitions are widespread, with notable departures due to misconduct (Exyn Technologies) and strategic disagreements (Core Laboratories), alongside CFO changes at major firms like Exelon and Sun Communities. Several companies are in distressed financial positions, including BioXcel and reAlpha, facing tight deadlines and regulatory hurdles. The overall sentiment is cautiously optimistic, with a clear trend toward leveraging capital markets for growth while managing leverage and liquidity.

50 high priority 50 total filings
· daily

Insider Trading Pulse — August 25, 2026

The August 25, 2026, insider trading digest reveals a bifurcated market with significant insider buying in select deep-value and special situation names, contrasted by a broad wave of insider selling, particularly in the technology and consumer sectors. The most notable buying signals come from Alibaba (Director Tsai Joseph C bought $10.4M), EBR Systems (10% owner bought $20.8M), and Borr Drilling (Director bought $875K), suggesting strong conviction in these companies' undervaluation or growth prospects. Conversely, a cluster of sales at Sea Ltd (COO sold $1.74M under 10b5-1 plan), Estee Lauder (Exec VP sold $554K), and QuantumScape (CTO sold $76.5K) raise caution flags. The data also reveals a significant number of routine, non-directional transactions (awards, tax withholdings, option exercises) at companies like Leggett & Platt and Commerce.com, which are neutral for sentiment. A key portfolio-level trend is the prevalence of 10b5-1 plan sales, which can mask bearish intent but still warrant monitoring. The absence of forward-looking guidance changes in this batch limits catalyst calendar building, but the insider activity patterns provide actionable signals for near-term positioning.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — August 25, 2026

The August 25, 2026 digest for the Dow Jones 30 is dominated by a coordinated wave of insider selling at Amazon, with six separate Form 4 filings showing top executives—including the CEO, CFO, and heads of AWS and Worldwide Stores—collectively cashing out over $8.2 million in stock. While all trades were executed under pre-arranged 10b5-1 plans, the sheer volume and breadth of selling across the C-suite raises a cautionary flag about near-term sentiment at current valuation levels. In contrast, Home Depot's 10-Q reveals a mixed operational picture: total sales grew 5.7% YoY, but the Pro segment saw a 7% comparable sales decline, and six-month operating income growth was a tepid 1.1%, suggesting margin pressure from elevated acquisition spending ($1.33B vs. $233M last year). The lone non-Amazon insider trade was a sale by the CEO of Optum at UnitedHealth Group, adding to the bearish insider tone across the stream. No forward-looking guidance changes or major capital allocation announcements were present in this batch, leaving the insider activity as the most actionable signal for the near term.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 25, 2026

Today's filings paint a stark picture of distress across micro-cap and pre-commercial biotech companies, with 6 out of 7 issuers receiving Nasdaq deficiency notices for bid price, market value, or late filing violations. The cluster of three late filers (BioRestorative, Maison Solutions, and La Rosa Holdings) signals systemic accounting and liquidity problems. La Rosa Holdings stands out as the most acute case, with liabilities exceeding assets by $7.8M and cash burning at a 26% QoQ rate. All companies have been granted extended compliance periods (late Q4 2026 through early Q2 2027), creating a series of critical 'cure-or-delist' deadlines. No insider trading activity or capital allocation events were reported in any filing, suggesting management teams are largely sidelined. The primary themes are Nasdaq delisting risks, going-concern doubts, and liquidity crises.

7 high priority 7 total filings
· daily

Global High-Priority Regulatory Events — August 25, 2026

The 50 filings from August 25, 2026, paint a picture of a market with significant distress signals and capital reallocation. A dominant theme is SPAC distress, where Black Hawk, Range Capital, and DT Cloud Star are all making monthly extension payments to avoid liquidation, while Future Vision II saw a 32.4% redemption rate ($20.6M) on its latest extension. Concurrently, there is a wave of M&A in the defense and life sciences sectors with high valuations, including a $2.3B SPAC merger for Ursa Major (hypersonics) and a stock-and-cash merger between MiMedx and Sanara MedTech. The regulatory environment is exceptionally active, with SEBI issuing multiple enforcement and recovery orders for market manipulation. Nasdaq compliance issues are rampant, with Datavault AI, Fathom Holdings, BEST SPAC I, Maison Solutions, and BioRestorative all receiving delisting-deficiency notices, highlighting a broad-based crisis among micro-cap equities. On the operational side, La Rosa Holdings shows a mixed picture with gross profit growth (+9.9%) masking a revenue decline (-18%) and a significant going-concern risk. The total capital being deployed for new renewable energy investments (Arvind Limited, Shriram Pistons) totals ₹27.6 Crore, signaling a clear shift toward captive solar power. Insider activity is starkly absent across these filings, which is a negative signal, as it suggests management teams are not buying their own stock. The most actionable signal is the 41.6% operating loss improvement at La Rosa Holdings against a backdrop of insolvency risk.

50 high priority 50 total filings
· daily

Biotech Small-Cap Approvals — August 25, 2026

The August 25, 2026 approval stream delivered four biosimilar (FALLBACK) approvals, with zero NMEs, zero label expansions, and zero bullish or bearish signals. All four approvals were rated neutral, reflecting generic entrants into established markets without disclosed peak sales or exclusivity data. The highest-conviction signal is the approval of NINTEDANIB ESYLATE by BIOCON PHARMA, as it targets a high-value orphan pulmonary fibrosis market with premium pricing potential, though commercial specifics remain NOT_DISCLOSED. The key risk is the lack of differentiation across all four approvals—ASCORBIC ACID (ZYDUS PHARMS), LISINOPRIL (ANNORA PHARMA), RIVAROXABAN (EPIC PHARMA LLC), and NINTEDANIB ESYLATE (BIOCON PHARMA)—which may face intense generic competition and pricing erosion without clear market positioning data.

4 total filings
· daily

Orphan Drug Approvals — August 25, 2026

The single approval in this period is a label expansion for Apellis Pharmaceuticals' PEGCETACOPLAN (EMPAVELI), classified as a 'fallback' type with a moderately bullish signal. There are no NMEs, biosimilars, or other label expansions, making this a low-volume, single-event period with no new therapeutic area clustering or competitive disruption. The highest-conviction signal is the label expansion itself, which may broaden the addressable patient population for EMPAVELI, though peak sales, exclusivity, and pricing power are not disclosed, limiting commercial conviction. The key watch item is the lack of disclosed commercial details and the absence of any other approvals, which reduces the actionable investment signals for the period.

1 total filings